Role and efficacy of denosumab in osteoporotic patients undergoing joint replacement surgery

Rohil Singh Kakkar; Ananya Pareek; Tarun Sharma; Rajendra Hegde

doi:10.18203/2349-2902.isj20251446

Authors

Rohil Singh Kakkar Department of Orthopaedic Surgery, Eternal Hospital Sanganer, Jaipur, Rajasthan, India
Ananya Pareek Department of Medical Oncology, RHL Renova Cancer Centre, Jaipur, Rajasthan, India
Tarun Sharma RPG Life Sciences Limited, Mumbai, Maharashtra, India
Rajendra Hegde RPG Life Sciences Limited, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-2902.isj20251446

Keywords:

Denbri, Joint replacement surgery, Total hip replacement, Total knee replacement, Denosumab, Osteoporosis, Bone mineral density

Abstract

Osteoporosis is a prevalent skeletal disorder characterized by decreased bone mass and structural deterioration, significantly increasing the risk of fractures. In joint replacement surgeries, compromised bone quality in osteoporotic patients poses substantial challenges, including an elevated risk of periprosthetic fractures and implant instability. Denosumab, a monoclonal antibody targeting receptor activator of nuclear factor-kappa B ligand (RANKL), has emerged as a potent antiresorptive agent with the potential to enhance surgical outcomes in these patients. This study systematically reviews and evaluates the role and efficacy of denosumab in improving bone mineral density (BMD), minimizing periprosthetic bone loss (PBL), and enhancing implant stability in osteoporotic patients undergoing joint replacement surgery. A comprehensive literature search was conducted utilizing PubMed, MEDLINE, and Cochrane Library databases, including randomized controlled trials (RCTs) and cohort studies evaluating the impact of denosumab on BMD, PBL, and implant stability in osteoporotic patients undergoing joint replacement. Six major RCTs were included in the analysis, consistently demonstrating that denosumab enhances BMD, reduces PBL, and improves implant stability. These findings suggest that denosumab is an effective therapeutic option for optimizing surgical outcomes in osteoporotic patients undergoing joint replacement, supporting its integration into perioperative management strategies.

Metrics

Metrics Loading ...

References

Kanis JA, McCloskey EV, Johansson H, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23-57. DOI: https://doi.org/10.1007/s00198-012-2074-y

Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-33. DOI: https://doi.org/10.1007/s00198-006-0172-4

Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520-6. DOI: https://doi.org/10.1002/jbmr.2269

Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761-7. DOI: https://doi.org/10.1016/S0140-6736(02)08657-9

Lewiecki EM, Bilezikian JP. Osteoporosis: clinical updates and emerging therapies. Lancet Diabetes Endocrinol. 2015;3(4):276-84.

Rosen CJ, Drezner MK, Bilezikian JP. The role of denosumab in the treatment of osteoporosis. Clin Ther. 2013;35(10):1636-49.

Watts NB, Bilezikian JP. Osteoporosis and fractures: an overview of the problem. Clin Ther. 2010;32(3):389-95.

McClung MR, Boonen S, Törring O. Fracture risk reduction with denosumab in osteoporosis: results from the FREEDOM trial and extension. N Engl J Med. 2012;367(12):1213-23.

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-809. DOI: https://doi.org/10.1056/NEJMoa074941

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65. DOI: https://doi.org/10.1056/NEJMoa0809493

Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM Extension. J Bone Miner Res. 2012;27(3):694-701. DOI: https://doi.org/10.1002/jbmr.1479

Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555-65. DOI: https://doi.org/10.1210/jc.2009-1947

Ferrari S, Reginster JY, Cortet B. Unmet needs in the management of postmenopausal osteoporosis in Europe. Arch Osteoporos. 2016;11(1):29. DOI: https://doi.org/10.1007/s11657-016-0292-1

Bone HG, Chapurlat R, Brandi ML. The effect of denosumab on bone mineral density and bone turnover: results of the FREEDOM Extension study. J Clin Endocrinol Metab. 2013;98(11):4482-92.

Aro HT, Nyström A, Sund R. Denosumab enhances periprosthetic bone density and reduces implant migration in total hip arthroplasty: a randomized controlled trial. JBMR Plus. 2019;3(10):e10217. DOI: https://doi.org/10.1002/jbm4.10217

Nyström A, Kiritopoulos D, Ullmark G, Sörensen J, Petrén-Mallmin M, Milbrink J, et al. Denosumab Prevents Early Periprosthetic Bone Loss After Uncemented Total Hip Arthroplasty: Results from a Randomized Placebo-Controlled Clinical Trial. J Bone Miner Res. 2020;35(2):239-47. DOI: https://doi.org/10.1002/jbmr.3883

Murahashi Y, Teramoto A, Jimbo S, Okada Y, Kamiya T, Imamura R, et al. Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty. Knee. 2020;27(2):580-6. DOI: https://doi.org/10.1016/j.knee.2019.12.010

Ledin H, Aspenberg P, Tägil M. Denosumab reduces early migration of tibial components in total knee arthroplasty: a randomized controlled trial. Acta Orthop. 2017;88(3):255-8. DOI: https://doi.org/10.1080/17453674.2017.1300746

Nakura H, Nozawa M, Shibuya T. Comparison of denosumab and risedronate for periprosthetic bone preservation in total hip arthroplasty: a randomized controlled trial. Osteoporos Int. 2023;34(1):122-35.

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-622. DOI: https://doi.org/10.1210/jc.2019-00221

Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2):S4-S9. DOI: https://doi.org/10.1016/j.bone.2005.11.024

Kendler DL, Marin F, Zerbini CAF. Effects of denosumab on bone mineral density and bone strength in postmenopausal women with osteoporosis: results from the FREEDOM Extension. J Clin Endocrinol Metab. 2018;103(3):852-60.